Avrobio makes way for GPCR biotech Tectonic Therapeutic in reverse merger
The path to an IPO looks a little greener in biotech these days, but private startups are still eyeing reverse mergers to land their Nasdaq footing, with Tim Springer’s Tectonic Therapeutic being the latest example.
The Boston-area biotech — founded by repeat biotech entrepreneur and Institute for Protein Innovation founder Springer and Harvard Medical School professor Andrew Kruse — will assume the public position of gene therapy maker Avrobio, which last summer ended development shortly after selling an asset to Novartis.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.